|
|
Volumn 14 Suppl 1, Issue , 2010, Pages 55-62
|
|
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
CISPLATIN;
CROSS LINKING REAGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
GEMCITABINE;
NAVELBINE;
RADIOSENSITIZING AGENT;
TOPOTECAN;
VINBLASTINE;
CANCER STAGING;
CARCINOMA;
COST BENEFIT ANALYSIS;
DISEASE COURSE;
DRUG COMBINATION;
ECONOMICS;
FEMALE;
HUMAN;
MORTALITY;
PATHOLOGY;
QUALITY ADJUSTED LIFE YEAR;
QUALITY OF LIFE;
REVIEW;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
UNITED KINGDOM;
UTERINE CERVIX TUMOR;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA;
CISPLATIN;
COST-BENEFIT ANALYSIS;
CROSS-LINKING REAGENTS;
DEOXYCYTIDINE;
DISEASE PROGRESSION;
DRUG THERAPY, COMBINATION;
FEMALE;
GREAT BRITAIN;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
QUALITY OF LIFE;
QUALITY-ADJUSTED LIFE YEARS;
RADIATION-SENSITIZING AGENTS;
TOPOTECAN;
TREATMENT OUTCOME;
UTERINE CERVICAL NEOPLASMS;
VINBLASTINE;
MLCS;
MLOWN;
|
|
EID: 84886942997
PISSN: None
EISSN: 20464924
Source Type: Journal
DOI: 10.3310/hta14suppl1/08 Document Type: Review |
|
Times cited : (13)
|
|
References (50)
|
